Drugs / MIB-725
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06815991 | Feb 2025 → Dec 2026 expected | — | Metro International Biotech, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIB-725 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06815991 ↗ |
| Route | Oral | “MIB-725 will be administered orally.” NCT06815991 ↗ |